Gastrointestinal Stromal Tumour | REGISTER
A Phase II, open-label, multicentre, dose escalation trial of imatinib followed by nilotinib in patients who have newly diagnosed, inoperable, gastrointestinal stromal tumour.
Schema
Summary
This is a Phase II, open label, multicentre study evaluating imantinib dose escalation followed by nilotinib after progressive disease, according to stratification into exon 11 and non-exon 11/WT mutational status. The functional response to therapy, as determined by FDG-PET, will be correlated with pharmacokinetics after administration.
